Dateline: A conference room somewhere inside Penn Medicine, where I am reporting live from the Germination Project’s annual Boot Camp, surrounded by twenty-three of Philadelphia’s most promising young Fellows, several centrifuges, and, as far as I can tell, zero people under the age of thirty who know or care that the King has arrived.
Let the record show: on July 24, 2026, LeBron James, a four-time NBA champion, four-time MVP, the league’s all-time leading scorer, and a man who has been famous since before some of these Germination Fellows were born, agreed to a two-year, $8 million contract with the Philadelphia 76ers. Governor Josh Shapiro, exercising what I can only assume is a constitutionally dubious but spiritually necessary gubernatorial power, declared it “LeBron James Day” in the Commonwealth of Pennsylvania. Tyrese Maxey, Jaylen Brown, VJ Edgecombe, and Joel Embiid will now share a backcourt and frontcourt with a 41-year-old man who once dropped 36 points on the Sixers in a building that no longer exists. This is, by any sane cultural metric, a five-alarm story.
It has been, in my professional and highly caffeinated observation, a two-alarm story at best, and one of those alarms was somebody’s phone buzzing with a Penn Medicine calendar invite.
READ: The Review by Ajay Raju | America’s future looks more like a rice paddy than a frontier (July 2, 2026)
Because here at Penn Medicine Boot Camp, and seemingly everywhere else with a Philadelphia area code, the actual main character of the week is not a basketball player. It is Dr. Carl June, the man who built CAR T-cell therapy into the first FDA-approved cellular treatment for lymphoma and leukemia, standing shoulder to shoulder with Dr. Drew Weissman, the Nobel laureate whose mRNA work with Katalin Karikó underwrote both the Pfizer and Moderna COVID vaccines and, in the university’s own quiet accounting, has generated more than a billion dollars in royalties. These two men are now formally collaborating. Wow!
Let me repeat for emphasis. June and Weissman are collaborating! CAR-T meets mRNA, the “living drug” meets the platform that can be reprogrammed in weeks instead of months, and treating it, from what I can gather between boot camp sessions, as a perfectly ordinary Monday. Weissman’s Institute for RNA Innovation now counts more than 550 researchers. June was just named to Forbes’ list of America’s 250 greatest innovators, alongside Weissman and Karikó, as a matter of course, the way other institutions announce a new parking structure.
I understand the assignment. I do. Watching June and Weissman work a room together is, for those of us who follow this sort of thing, the scientific equivalent of watching peak Michael Jordan and peak LeBron James suit up for the Sixers, except one of them didn’t need free agency, just a hallway. It is, genuinely, a big deal. But I miss the old media ecosystem that would not be so thoroughly captured by these scientific miracles that it forgets how to be excited about anything smaller than curing cancer before lunch.
READ: The Review by Ajay Raju | America’s future looks more like a rice paddy than a frontier (July 2, 2026)
Because somewhere in the last several months, Philadelphia’s collective attention span narrowed to a single hallway at 34th and Spruce. The newscasters and the group chats seem to have no room for anything other than one miracle at a time. I miss when a Governor could proclaim a holiday for a basketball player and it would trend for more than the length of a Wawa hoagie order. I miss when the NFL’s September 9 kickoff, Patriots at Seahawks, the defending champs opening at home, could get a full segment instead of a chyron crawl squeezed between updates on lipid nanoparticle delivery mechanisms. I miss discussing Victor Wembanyama’s summer the way we used to discuss things that weren’t happening inside a Perelman School lab. I miss a news cycle that had bandwidth left over for Gaza, for the fragile ceasefire now well into its tenth month of very partial compliance, for whatever the Board of Peace is or isn’t accomplishing this week, for Trump, for the actual named human beings running for actual office in November. There is a whole world happening outside the Institute for RNA Innovation. Where’s the coverage?
Instead, I am here, at Penn Medicine, watching twenty-three of the sharpest sixteen year-olds in Philadelphia debate gene therapy delivery mechanisms with more animation than anyone in this city has spent on the fact that LeBron James, again, the LeBron Freaking James, just picked their hometown team over Cleveland, Miami, and roughly eight other suitors, for less money than a mid-tier associate at my own firm makes in a good bonus year. He took a pay cut. For Philadelphia. And the loudest reaction I’ve heard about it all week came from a Fellow who looked up from her CRISPR slide deck just long enough to say, “Wait, LeBron’s a Sixer now?” before returning to her spreadsheet.
Maybe that’s the actual headline. Not that a legend joined a team for the love of the game, but that in this city, at this particular moment, even a legend is competing for attention with people who make biblical miracles an ordinary news day. Dr. June, Dr. Weissman: enjoy the spotlight. You’ve earned it, but I wish we also had some room left in the chat rooms to discuss the KING.